Here are 1-3 brief analogies for Catalyst Pharmaceuticals (CPRX):

• Imagine a more focused version of Alexion Pharmaceuticals (historically known for its rare disease drugs), but specifically targeting rare neuromuscular and neurological conditions.
• Similar to how Jazz Pharmaceuticals specializes in specific therapeutic areas like sleep disorders and oncology, Catalyst Pharmaceuticals is a commercial-stage company dedicated to rare neuromuscular diseases.

• Firdapse: Amifampridine phosphate tablets primarily for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), and in development for other neuromuscular and neurological diseases.
• Ruzurgi: A therapy specifically for the treatment of pediatric patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
• Generic Sabril tablets: A generic medication being developed and commercialized through a collaboration and license agreement.

Catalyst Pharmaceuticals (CPRX), as a biopharmaceutical company commercializing prescription therapies, sells its products primarily to other companies within the pharmaceutical supply chain, rather than directly to individual patients. The end-users of its therapies (such as Firdapse for LEMS patients) receive the medication through healthcare providers and pharmacies.

The major customers for a pharmaceutical manufacturer like Catalyst Pharmaceuticals are typically large pharmaceutical wholesale distributors. These distributors purchase drugs directly from manufacturers and then distribute them to pharmacies, hospitals, and other healthcare providers across the United States. While the background information does not explicitly name Catalyst Pharmaceuticals' specific customers, the largest and most common major customers for U.S. pharmaceutical manufacturers include:

• McKesson Corporation (MCK)
• Cencora (formerly AmerisourceBergen, COR)
• Cardinal Health, Inc. (CAH)

These three companies collectively account for a significant portion of pharmaceutical distribution in the United States and serve as critical intermediaries between drug manufacturers and the points of care where patients receive their medications. Additionally, given the rare disease focus of Catalyst's products, sales may also be directed to specialty pharmacies, which manage and dispense complex and high-cost medications, often supplied through or in conjunction with these major wholesalers.

Richard Daly, President and Chief Executive Officer

Mr. Daly assumed the role of President and CEO of Catalyst Pharmaceuticals in January 2024, having previously served on its Board of Directors for nine years. He brings decades of experience in the pharmaceutical industry, including leadership positions at various biotech companies. Prior to joining Catalyst, Mr. Daly was the President of CARsgen Therapeutics Corporation (January 2022–August 2023), Chief Operating Officer at BeyondSpring Pharmaceuticals (July 2018–January 2022), and Chairman and CEO of Neuralstem, Inc. (February 2016–July 2018). He also served as President of AstraZeneca US Diabetes (February 2013–September 2014), where he led a $1.2 billion revenue division and launched the orphan rare disorder drug Myalept. Mr. Daly has also held senior leadership roles at Takeda and TAP Pharmaceuticals. He has served on the board of directors for Opiant Pharmaceuticals and Synergy Pharmaceuticals.

Michael Kalb, Executive Vice President and Chief Financial Officer

Mr. Kalb became the Executive Vice President and Chief Financial Officer of Catalyst Pharmaceuticals in January 2024. He has over 30 years of experience in the financial services and pharmaceutical industries. Before joining Catalyst, Mr. Kalb served as CFO at Impel Pharmaceuticals, Inc. (May 2023–December 2023). He was also the Executive Vice President and CFO of CinCor Pharma, Inc. (November 2022–March 2023), which was subsequently sold to AstraZeneca. His career also includes roles as Senior Vice President and CFO at Amarin Corporation (June 2016–June 2022) and senior finance leadership, including Group Vice President and CFO, at Taro Pharmaceutical Industries, Ltd. (June 2009–June 2016).

Patrick J. McEnany, Co-Founder and Non-Executive Chairman of the Board

Mr. McEnany co-founded Catalyst Pharmaceuticals and has served as a director since its formation in January 2002. He was the President and CEO until his retirement on December 31, 2023, and has been Chairman since March 2006. Prior to Catalyst, Mr. McEnany was Chairman and CEO of Royce Laboratories, Inc., a generic pharmaceutical manufacturer, from 1991 to 1997. After Royce Laboratories merged with Watson Pharmaceuticals, Inc., he served as President of the Royce Laboratories subsidiary and Vice President of Corporate Development for Watson Pharmaceuticals until 1999. He has served as a director for numerous public companies over the last three decades.

Steven Miller, PhD, Executive Vice President, Chief Operating Officer, and Chief Scientific Officer

Dr. Miller is the Executive Vice President, Chief Operating Officer, and Chief Scientific Officer of Catalyst Pharmaceuticals. He joined Catalyst in 2007 and has been instrumental in managing the in-licensing of key products, including Firdapse. His career, spanning over 25 years prior to Catalyst, includes experience in chemistry and manufacturing controls, quality systems, validation, contract operations, and development planning. He previously held roles as Executive Director of R&D Operations at Watson Pharmaceuticals and VP of Research and Product Development at Royce Laboratories.

Gary Ingenito, M.D., Ph.D., Chief Medical and Regulatory Officer

Dr. Ingenito is the Chief Medical and Regulatory Officer at Catalyst Pharmaceuticals. He joined Catalyst as Chief Medical Officer in June 2015 and assumed responsibility for regulatory operations in February 2016. With over 25 years of experience in drug development, his expertise spans clinical research, regulatory affairs, pharmacovigilance, and medical affairs. Prior to Catalyst, Dr. Ingenito held leadership positions at Sandoz, where he became Head of Medical Affairs, and spent eight years at Otsuka Pharmaceuticals, overseeing the approval of anti-infective, cardiovascular, and central nervous system products. He also held positions at Corning-Besselaar, SFBC International, Angiotech Pharmaceuticals, Biotest Pharmaceuticals, and Boehringer-Ingelheim Pharmaceuticals, where he was Head of Regulatory Affairs North America for biosimilars.

The key risks to Catalyst Pharmaceuticals (CPRX) include its significant reliance on its flagship drug Firdapse, potential generic competition for its key products, and the inherent risks associated with a concentrated product portfolio and a limited internal development pipeline.

1. Reliance on Firdapse and Generic Competition: Catalyst Pharmaceuticals' revenue is heavily concentrated on Firdapse, which has been described as its "cash cow" and has, at times, accounted for over 90% of its total sales. While the company has successfully settled patent litigation with Teva Pharmaceuticals and Lupin Ltd., delaying generic versions of Firdapse until at least February 2035, ongoing patent litigation with Hetero Labs Ltd. still poses a significant risk. A negative outcome in this remaining litigation could lead to earlier generic market entry and materially impact the company's revenues. The expiration of orphan drug exclusivity for Firdapse in November 2025 was a previous concern, but patent settlements have largely mitigated this immediate threat. Nevertheless, the heavy dependence on Firdapse leaves the company vulnerable to any shifts in market dynamics, competitive pressures, or evolving treatment standards.
2. Product Concentration and Limited Pipeline Depth: Beyond Firdapse, Catalyst Pharmaceuticals primarily relies on a limited number of products, including AGAMREE and FYCOMPA, for the majority of its revenue. The company's business model is largely focused on acquiring existing molecules rather than extensive internal drug discovery and development. This results in a relatively narrow pipeline with few late-stage assets to drive significant future growth. This high revenue concentration on a few key products exposes Catalyst to considerable risk if any of these products face unexpected challenges, such as trial failures, unsuccessful label expansions, or increased competition. For example, FYCOMPA is facing impending generic competition.
3. Pricing Scrutiny and Public Perception: The high price of Firdapse, with an annual list price previously noted around $375,000, has historically generated public controversy and criticism from lawmakers and patient groups. Some neuromuscular physicians and LEMS patients continue to voice concerns about Firdapse's pricing to the media, the FDA, and politicians. While the exact impact of these activities on the business is difficult to quantify, sustained negative public perception could potentially influence regulatory decisions, payer negotiations, or overall market acceptance in the long term.

Catalyst Pharmaceuticals (CPRX) focuses on therapies for rare neuromuscular and neurological diseases. The addressable markets for its main products and those in development are as follows:

• Firdapse (amifampridine phosphate tablets) for Lambert-Eaton Myasthenic Syndrome (LEMS): The estimated addressable market for Firdapse in the U.S. for LEMS is approximately $1 billion. The total LEMS treatment market in North America was valued at USD 47.61 million in 2024 and is projected to reach USD 78.27 million by 2032. Globally, the LEMS treatment market was valued at USD 820 million in 2024 and is expected to reach USD 1,363.23 million by 2032.

• Ruzurgi for pediatric LEMS patients: Ruzurgi's FDA approval was withdrawn in 2022 due to a lawsuit by Catalyst Pharmaceuticals concerning Firdapse's orphan-drug exclusivity. Therefore, an addressable market size for Ruzurgi cannot be provided at this time as it is not actively marketed.

• Firdapse for MuSK antibody positive Myasthenia Gravis (in development): Firdapse is in development for this indication. Myasthenia Gravis (MG) has an estimated prevalence of approximately 37 per 100,000 individuals in the United States as of 2021. The U.S. Myasthenia Gravis market was valued at approximately USD 2.9 billion in 2024. Globally, the Myasthenia Gravis treatment market size was estimated at USD 4.5 billion in 7MM (United States, EU4, United Kingdom, and Japan) in 2024 and is projected to grow to USD 3.29 billion by 2034. MuSK antibody positive MG patients represent about 5-8% of the estimated 60,000 Myasthenia Gravis patients.

• Firdapse for Spinal Muscular Atrophy Type 3 (in development): Firdapse is being developed for Spinal Muscular Atrophy (SMA) Type 3. The global spinal muscular atrophy treatment market size was estimated at USD 4.40 billion in 2024 and is projected to reach USD 13.09 billion by 2030, with a CAGR of 18.0% from 2025 to 2030. North America holds the largest share of the global SMA market, with the U.S. being the largest individual market.

• Firdapse for Hereditary Neuropathy with Liability to Pressure Palsies (in development): Firdapse is also being developed to treat Hereditary Neuropathy with Liability to Pressure Palsies (HNPP). The prevalence of HNPP is estimated to range from 0.84 to 16 per 100,000 individuals worldwide. A specific addressable market size in dollar value for this indication is not available in the provided information.

Catalyst Pharmaceuticals (CPRX) anticipates several key drivers for future revenue growth over the next two to three years, primarily stemming from the continued performance of its commercial products and strategic expansion initiatives:

1. Continued Growth of FIRDAPSE: FIRDAPSE, approved for Lambert-Eaton Myasthenic Syndrome (LEMS), is expected to maintain robust growth through continued patient identification and market penetration. The company reported an 18.3% increase in FIRDAPSE net revenue in Q4 2025 compared to Q4 2024, and full-year 2025 growth of 17.1%. Catalyst Pharmaceuticals has provided 2026 guidance for FIRDAPSE net product revenue to be between $435 million and $450 million, representing a projected growth of 21.4% to 25.6% over 2025. This growth is also attributed to lifecycle management initiatives in both idiopathic and cancer-associated LEMS.
2. Strong Uptake and Market Penetration of AGAMREE: AGAMREE (vamorolone), a differentiated corticosteroid treatment for Duchenne muscular dystrophy (DMD), is demonstrating significant market adoption. The product's revenue increased by a remarkable 67.5% in Q4 2025 over Q4 2024. For 2026, Catalyst Pharmaceuticals forecasts AGAMREE net product revenue to be between $140 million and $150 million, which is a projected increase of 19.6% to 28.1%. This growth is supported by strategic efforts for deeper market penetration and expansion initiatives, including ongoing clinical studies.
3. Expansion into New Indications and Lifecycle Management: Catalyst Pharmaceuticals is actively pursuing lifecycle management initiatives for its existing products to expand their utility and reach. For FIRDAPSE, this includes continued focus on idiopathic and cancer-associated LEMS. For AGAMREE, the company is engaged in ongoing clinical studies and exploring new indications, which could broaden its addressable patient population. The company also plans to showcase real-world findings related to vamorolone in Duchenne Muscular Dystrophy at scientific conferences.
4. Strategic Business Development and Acquisitions: Catalyst Pharmaceuticals has a stated "buy-and-build growth strategy" and is continuously evaluating strategic opportunities to strengthen its product portfolio and expand its reach to serve more patients with rare diseases. In 2025, the company assessed over 100 potential acquisition targets, indicating an active pursuit of external growth. The company also highlights over $1 billion in capacity for future transactions.
5. Effective Commercial Execution and Patient Support Programs: The company emphasizes disciplined commercial execution and the success of its "Catalyst Pathways" patient support program. This program is designed to accelerate patient access to therapies, ensure compliance, and optimize care, contributing to high prescription compliance rates for both FIRDAPSE and AGAMREE. These operational efficiencies and patient-centric approaches are expected to continue driving sustained revenue growth.